These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37168878)

  • 21. Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland.
    Knetki-Wróblewska M; Kowalski DM; Czyżewicz G; Bryl M; Wrona A; Dziadziuszko R; Kieszko R; Milanowski J; Świniuch D; Ramlau R; Krzakowski M
    Adv Respir Med; 2020; 88(3):189-196. PubMed ID: 32706102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.
    White MN; Piotrowska Z; Stirling K; Liu SV; Banwait MK; Cunanan K; Sequist LV; Wakelee HA; Hausrath D; Neal JW
    Clin Lung Cancer; 2021 May; 22(3):201-209. PubMed ID: 33610453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L).
    Yamaguchi H; Wakuda K; Fukuda M; Kenmotsu H; Mukae H; Ito K; Chibana K; Inoue K; Miura S; Tanaka K; Ebi N; Suetsugu T; Harada T; Kirita K; Yokoyama T; Nakatani Y; Yoshimura K; Nakagawa K; Yamamoto N; Sugio K
    J Thorac Oncol; 2021 Dec; 16(12):2121-2132. PubMed ID: 34419684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC.
    Zheng MM; Li YS; Tu HY; Jiang BY; Yang JJ; Zhou Q; Xu CR; Yang XR; Wu YL
    J Thorac Oncol; 2021 Feb; 16(2):250-258. PubMed ID: 33122107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic.
    Lakkunarajah S; Truong PT; Bone JN; Hughesman C; Yip S; Alex D; Hart J; Pollock P; Egli S; Clarkson M; Lesperance M; Ksienski D
    Transl Lung Cancer Res; 2023 Jul; 12(7):1454-1465. PubMed ID: 37577326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
    Cheng Y; He Y; Li W; Zhang HL; Zhou Q; Wang B; Liu C; Walding A; Saggese M; Huang X; Fan M; Wang J; Ramalingam SS
    Target Oncol; 2021 Mar; 16(2):165-176. PubMed ID: 33544337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
    Soo RA; Han JY; Dafni U; Cho BC; Yeo CM; Nadal E; Carcereny E; de Castro J; Sala MA; Bernabé R; Coate L; Provencio Pulla M; Garcia Campelo R; Cuffe S; Hashemi SMS; Früh M; Massuti B; Garcia-Sanchez J; Dómine M; Majem M; Sanchez-Torres JM; Britschgi C; Pless M; Dimopoulou G; Roschitzki-Voser H; Ruepp B; Rosell R; Stahel RA; Peters S;
    Ann Oncol; 2022 Feb; 33(2):181-192. PubMed ID: 34839016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
    Auliac JB; Pérol M; Planchard D; Monnet I; Wislez M; Doubre H; Guisier F; Pichon E; Greillier L; Mastroianni B; Decroisette C; Schott R; Le Moulec S; Arrondeau J; Cortot AB; Gerinière L; Renault A; Daniel C; Falchero L; Chouaid C
    Lung Cancer; 2019 Jan; 127():96-102. PubMed ID: 30642559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors.
    Bouchez C; Pluvy J; Soussi G; Nguenang M; Brosseau S; Tourne M; Collin M; Théou-Anton N; Guyard A; Ammar J; Khalil A; Zalcman G; Gounant V
    BMC Cancer; 2020 Dec; 20(1):1186. PubMed ID: 33272243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).
    Popat S; Jung HA; Lee SY; Hochmair MJ; Lee SH; Escriu C; Lee MK; Migliorino MR; Lee YC; Girard N; Daoud H; Märten A; Miura S
    Lung Cancer; 2021 Dec; 162():9-15. PubMed ID: 34649106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study.
    Akli A; Girard N; Fallet V; Rousseau-Bussac G; Gounant V; Friard S; Trédaniel J; Dujon C; Wislez M; Duchemann B; Giroux-Leprieur E
    Target Oncol; 2022 Nov; 17(6):675-682. PubMed ID: 36129569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study.
    Zhou B; Gong Q; Li B; Qie HL; Li W; Jiang HT; Li HF
    J Clin Pharm Ther; 2022 May; 47(5):643-651. PubMed ID: 35023208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracranial Outcomes of De Novo Brain Metastases Treated With Osimertinib Alone in Patients With Newly Diagnosed EGFR-Mutant NSCLC.
    Imber BS; Sehgal R; Saganty R; Reiner AS; Ilica AT; Miao E; Li BT; Riely GJ; Yu HA; Panageas KS; Young RJ; Pike LRG; Moss NS
    JTO Clin Res Rep; 2023 Dec; 4(12):100607. PubMed ID: 38124791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
    Papadimitrakopoulou VA; Mok TS; Han JY; Ahn MJ; Delmonte A; Ramalingam SS; Kim SW; Shepherd FA; Laskin J; He Y; Akamatsu H; Theelen WSME; Su WC; John T; Sebastian M; Mann H; Miranda M; Laus G; Rukazenkov Y; Wu YL
    Ann Oncol; 2020 Nov; 31(11):1536-1544. PubMed ID: 32861806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world data on treatment outcomes in
    Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M-positive Non-Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study.
    Xing L; Pan Y; Shi Y; Shu Y; Feng J; Li W; Cao L; Wang L; Gu W; Song Y; Xing P; Liu Y; Gao W; Cui J; Hu N; Li R; Bao H; Shao Y; Yu J
    Clin Cancer Res; 2020 Dec; 26(23):6168-6175. PubMed ID: 32817079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases.
    Ye Q; Xu Y; Zhao J; Gao X; Chen M; Pan R; Zhong W; Wang M
    Transl Oncol; 2023 May; 31():101637. PubMed ID: 36867956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.
    Wang X; Cai J; Zeng Z; Liu A
    BMC Cancer; 2021 Jul; 21(1):873. PubMed ID: 34330231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates.
    Langer C; Hirsh V
    Lung Cancer; 2010 Jan; 67(1):4-11. PubMed ID: 19939491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
    Goss G; Tsai CM; Shepherd FA; Bazhenova L; Lee JS; Chang GC; Crino L; Satouchi M; Chu Q; Hida T; Han JY; Juan O; Dunphy F; Nishio M; Kang JH; Majem M; Mann H; Cantarini M; Ghiorghiu S; Mitsudomi T
    Lancet Oncol; 2016 Dec; 17(12):1643-1652. PubMed ID: 27751847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.